Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2024

Phase 2 trial of deucravacitinib in psoriatic arthritis: Biomarkers associated with disease activity, pharmacodynamics, and clinical responses

Arthritis Rheumatol 2024 doi: 10.1002/art.42921 Epub ahead of print

Gao L,

Hu Y,

Nowak M,

Banerjee S,

Catlett I

FitzGerald, et al. found that Deucravacitinib significantly impacted biomarkers associated with TYK2 signalling pathways of key inflammatory cytokines, including IL-23 and Type I IFN, and those related to collagen matrix turnover.

Keywords:

January 2024

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, Phase 3 trial

J Dermatol 2024;00:1–15. doi: 10.1111/1346-8138.17074

Imafuku S,

Okubo Y,

Tada Y,

Shao Y,

Week 16 coprimary endpoints of PASI 75 response and sPGA score improved in the majority of patients and was overall maintained through week 52. Deucravacitinib therapy was also associated with a low AE rate. This study presented results from the POETYK PSO-4 trial on the safety and efficacy of deucravacitinib 6mg QD in Japanese patients with psoriasis.

Keywords:

Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the Phase 3 POETYK trials

Br J Dermatol 2024. doi: 10.1093/bjd/ljae014. Epub ahead of print

Sofen H,

Paul C,

Kisa RM,

Buck A,

Banerjee S,

Thaçi D,

Blauvelt A

Researchers reported the safety and efficacy of deucravacitinib over 2 years in patients with chronic plaque PsO. The most frequently reported AEs were nasopharyngitis, URTI, and COVID-19.

Keywords:

August 2023

Efficacité et innocuité du brepocitinib, inhibiteur de TYK2/JAK1, dans le traitement du rhumatisme psoriasique actif : Essai contrôlé randomisé de phase IIb

Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519

Mease P,

Helliwell P,

Silwinska-Stanczyk P,

Miakisz M,

Ostor A,

Peeva E,

Vincent MS,

Sun Q,

Sikirica V,

Winnette R,

Qiu R,

Li G,

Feng G,

Beebe JS,

Martin DA.

Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.

Keywords:

December 2022

Deucravacitinib dans le psoriasis modéré à sévère

Immunotherapy. 2022 doi: 10.2217/imt-2022-0109

Vu A,

Maloney V,

Gordon KB

Deucravacitinib demonstrates promising results as a TYK2-specific immunotherapy and shows considerable efficacy yet is able to avoid the side effect profile observed with other JAK inhibitors.

Keywords:

September 2022

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, Phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

J Am Acad Dermatol 2023;88:40–51. doi: 10.1016/j.jaad.2022.08.061

Sofen H,

Foley P,

Rich P,

Paul C,

Bagel J,

Kundu S,

This Phase 3 study by Strober, et al. reports deucravacitinib superiority to placebo and apremilast in patients with PsO. The authors found that deucravacitinib had significantly higher rates of PASI 75 and sPGA achievement than placebo and deucravacitinib.

Keywords:

July 2022

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled Phase 3 POETYK PSO-1 trial

J Am Acad Dermatol 2023;88:29–39. doi: 10.1016/j.jaad.2022.07.002

Papp KA,

Kundu S,

Deucravacitinib has shown efficacy in the treatment of both skin and joint disease. As a result, researchers sought to compare the efficacy and safety of deucravacitinib versus placebo and apremilast in adults with moderate to severe plaque PsO.

Keywords:

June 2022

Efficacité et innocuité du Deucravacitinib, un inhibiteur sélectif de TYK2, dans un essai de phase II dans le rhumatisme psoriasique

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2021-221664

Neal J,

Kim J,

Singhal S,

Nowak M,

Banerjee S

In this study Mease, et al. aimed to evaluate the efficacy and safety of deucravacitinib in patients with active PsA. Treatment with the selective TYK2i deucravacitinib was well tolerated and resulted in greater improvements than placebo in ACR-20 as well as Multiplicity-controlled secondary endpoints and other exploratory efficacy measures in patients.

Keywords:

October 2020

Caractérisation Préclinique de l'Itacitinib (INCB039110), un Nouvel Inhibiteur Sélectif de JAK1, Pour le Traitement des Maladies Inflammatoires

European Journal of Pharmacology. 2020 Oct 15;885:173505. doi: 10.1016/j.ejphar.2020.173505

He X,

Li J,

Shin N,

Sarah S,

Xue CB,

Peel M,

Burke K,

Oliver J,

Fay B,

Yao W,

Huang T,

Zhang Y,

Itacitinib is an orally active JAK inhibitor and effectively delayed disease onset, reduced symptom severity, and accelerated recovery of inflammatory diseases in mouse models. Covington M et al demonstrated itacitinib’s high selectivity for JAK 1, its inhibition on IL-2 induced T cell proliferation and JAK/STAT signalling, its ability to also inhibit of the JAK/STAT pathway in response to IL-6 stimulation, and its effect on rat adjuvant induced arthritis model. The study used recombinant enzym...

Keywords:

September 2019

Comparaison du Baricitinib, Upadacitinib et Tofacitinib médié par la régulation de la signalisation des cytokines dans les sous-populations de leucocytes humains

Arthritis Res Ther. 2019 Aug 2;21(1):183

Lee J,

Na S,

Rocha G,

Zhang X,

Different JAKinibs modulated distinct cytokine pathways to varying degrees, and no agent potently or continuously inhibited an individual cytokine signalling pathway throughout the dosing interval. This study aimed to compare the in vitro cellular pharmacology of BARI, TOF and UPA across relevant leukocyte subpopulations, coupled with their in vivo PK, to determine their effects on distinct cytokine pathways. Peripheral blood mononuclear cells from healthy donors were incubated with different JA...